Organon & Co | OGN - Current Assets


Organon & Co reported $5.37B in Current Assets for its fiscal quarter ending in September of 2026.





Current Assets Change Date
Bristol-Myers Squibb USD 29.77B 1.19B Sep/2026
Celltrion KRW 493.66B 12.09B Jun/2026
Cspc Pharmaceutical CNY 22.25B 359.48M Dec/2025
Deva Holding AS TRY 9.13B 1.61B Sep/2023
Dianthus Therapeutics USD 856.04M 41.5M Sep/2026
Divis Laboratories Ltd INR 124.39B 13.43B Sep/2026
Gilead Sciences USD 16.55B 4.02B Sep/2026
Glaxosmithkline GBP 17.9B 134M Sep/2026
Kangmei Pharma CNY 6.66B 143.43M Jun/2026
Knight Therapeutics CAD 394.84M 5.86M Dec/2025
Laboratorios Farma EUR 509.33M 128.63M Dec/2023
Malin Corporation EUR 62.6M 26.7M Dec/2024
Medical Developments International AUD 33.75M 1.79M Dec/2025
Merck USD 38.94B 2.26B Sep/2026
Neuren Pharmaceuticals AUD 332.23M 11.98M Dec/2025
Novartis USD 28.75B 2.14B Sep/2026
Organigram Holdings CAD 280.09M 30M Jun/2026
Organon & Co USD 5.37B 258M Sep/2026
Ovoca Bio EUR 2.07M 510K Dec/2025
Pharma Mar EUR 295.56M 14.62M Sep/2026
Qiagen NV USD 1.66B 116.37M Jun/2026
Sartorius EUR 1.65B 8.4M Sep/2026
Sino Biopharmaceutical CNY 33.82B 9.13B Jun/2025
Tilray USD 729.32M 28.18M Sep/2025
Zealand Pharma A/S 15.02B 652.12M Mar/2026